Table 2 Incidences of fungal diseases in the whole hospital and in intensive care units, in 2019 and in 2020, for non-COVID-19 and COVID-19 patients
From: Impact of COVID-19 pandemic on antifungal consumption: a multicenter retrospective analysis
Year | 2019 | 2020 | ||||
|---|---|---|---|---|---|---|
Number of patients | Number of patients | Variation (%) 2019 vs 2020 (p =) | Number of COVID-19 patients | Number of non-COVID-19 patients | Difference (%) COVID-19 vs non-COVID-19 patients (p =) | |
n = 402,426 n (%) | n = 360,514 n (%) | n = 5650 n (%) | n = 354,864 n (%) | |||
Whole hospital | ||||||
Invasive fungal diseases | 892 (0.22) | 843 (0.23) | + 4.3 (p = 0.266) | 58 (1.0) | 785 (0.22) | + 78.0 (p < 0.001) |
Invasive aspergillosis | 341 (0.09) | 279 (0.07) | − 28.6 (p = 0.261) | 38 (0.67) | 241 (0.07) | + 89.6 (p < 0.001) |
Invasive candidiasis | 502 (0.12) | 540 (0.15) | + 20.0 (p = 0.003) | 20 (0.35) | 520 (0.15) | + 57.1 (p < 0.001) |
Invasive mucormycosis | 38 (0.009) | 12 (0.003) | − 66.0 (p = 0.002) | 0 (0) | 12 (0.003) | NA (p = 1) |
Cutaneous mucormycosis | 4 (0.001) | 2 (0.0006) | − 40.0 (p = 0.501) | 0 (0) | 2 (0.0006) | NA (p = 1) |
Cryptococcosis | 7 (0.002) | 10 (0.003) | + 50.0 (p = 0.344) | 0 (0) | 10 (0.003) | NA (p = 1) |
n = 22,255 n (%) | n = 20,344 n (%) | n = 1418 n (%) | n = 19,121 n (%) | |||
|---|---|---|---|---|---|---|
Intensive care units | ||||||
Invasive fungal diseases | 290 (1.3) | 336 (1.7) | + 23.5 (p = 0.003) | 53 (3.7) | 283 (1.5) | + 59.5 (p < 0.001) |
Invasive aspergillosis | 61 (0.27) | 98 (0.5) | + 46.0 (p < 0.001) | 40 (2.8) | 58 (0.3) | + 89.3 (p < 0.001) |
Invasive candidiasis | 218 (0.98) | 230 (1.1) | + 10.9 (p = 0.129) | 13 (1.1) | 217 (1.1) | 0 (p = 0.455) |
Invasive mucormycosis | 7 (0.03) | 4 (0.02) | − 33.3 (p = 0.453) | 0 (0) | 4 (0.02) | NA (p = 1) |
Cutaneous mucormycosis | 4 (0.02) | 1 (0.005) | + 75.0 (p = 0.246) | 0 (0) | 1 (0.005) | NA (p = 1) |
Cryptococcosis | 0 (0) | 3 (0.01) | NA (p = 1) | 0 (0) | 3 (0.02) | NA (p = 1) |